Abstract: The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing.

Abstract: The present invention provides a pharmaceutical composition for suppressing angiogenesis, containing heat shock protein 27 (HSP27) or a nucleic acid encoding HSP27. In addition, the present invention provides a pharmaceutical composition for treating cancer, containing HSP27 or a nucleic acid encoding HSP27. Additionally, the present invention provides a method of suppressing the in vitro growth of endothelial cells using HSP27. Further, the present invention provides a method of screening an active material for suppressing angiogenesis or an active material for treating cancer, comprising the following steps: processing endothelial cell lines into samples, respectively; measuring the content of HSP27 in an endothelial cell line; and selecting the sample in which the content of HSP27 in an endothelial cell line is increased compared with a control group.

Abstract: The present invention relates to a pharmaceutical composition for promoting angiogenesis, containing an antibody that specifically binds to heat shock protein (HSP) 27. In addition, the present invention relates to a pharmaceutical composition containing an antibody that specifically binds to HSP 27, for treating an angiogenesis-dependent ailment selected from a group consisting of a wound, chronic ulcer, ischemic stroke, myocardial infarction, angina pectoris, and cerebrovascular dementia. In addition, the present invention relates to a method for promoting the in vitro growth of endothelial cells using an antibody that specifically binds to HSP27.

Abstract: Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by the gene is also provided. Also, a method is provided for screening an anticancer agent, which comprises: (A) quantitatively analyzing expression of WIG1 and/or YPEL5 at an mRNA or protein level in a tumor cell which is not treated with a candidate for an anticancer agent; (B) quantitatively analyzing expression of the gene at an mRNA or protein level in a tumor cell after treatment of the candidate for an anticancer agent; and (C) selecting the candidate if the expression level of the gene is increased in step (B), compared to step (A).

Abstract: The present disclosure relates to a deacetylation hydrolase of a hyaluronic acid a hyaluronic acid deacetylated by same and a derivative thereof. The deacetylated hyaluronic acid and the derivative thereof have the following characteristic: a delayed initial decomposition rate on a living body; minimized decrease of molecular weight and viscosity; accelerated gelation due to a lower gelation temperature than the gelation temperature for a non-deacetylated hyaluronic acid; and an hMSC survival rate that is hardly affected by increased concentration of the deacetylated hyaluronic acid and the derivative thereof in a culture medium. As a result, the deacetylated hyaluronic acid and the derivative thereof can be useful as a bioingredient such a delivery system for a cell, gene, drug, and the like, or a support for tissue engineering, etc.

Abstract: A pharmaceutical composition for the treatment of malignant tumors comprising a human p31comet gene encoding protein represented by SEQ ID NO: 3 or 4 as an effective component is provided. The pharmaceutical composition can suppress cancer cell growth, induce apoptosis and kill cells by overexpressing p31comet in the solid malignant tumor cells. Therefore, the pharmaceutical composition can be effectively used for gene therapy.

Abstract: A multi-leaf collimator device for radiotherapy, including: a frame that has a box shape and has through-holes formed in top and bottom surfaces thereof; a plurality of collimators that are received in the frame, wherein each of the collimators includes a rack gear formed on the top surface of the collimator, the collimators are symmetrically arranged in a left-right direction about a central portion of the frame, and are slidably provided on the frame; and a motion driving unit that includes a pinion gear that is formed to be detachable from the rack gear formed on the top surface of the collimator, and is provided on the frame to move the pinion gear in a front-back direction of the frame and an up-down direction of the frame.

Abstract: Provided are an isolated protein derived from an N-terminal of HveA/HVEM and having activity of increasing the cell infectivity of herpes simplex virus (HSV) and use thereof.

Abstract: A composition for detecting a marker for the diagnosis or prognosis of liver cancer is disclosed. The composition includes an agent capable of assessing the expression level of UQCRH (ubiquinol-cytochrome c reductase hinge protein). In addition, a kit having the composition, a microarray for the diagnosis of liver cancer using the marker, and a method for detecting the marker, and predicting recurrence following surgery in liver cancer patients are disclosed. The marker is able to contribute to the early diagnosis of liver cancer and prediction of recurrence following surgery and survival of liver cancer patients who have undergone hepatic resection, and also is significant for being a promising therapeutic target for liver cancer.

Abstract: The present disclosure relates to a Panax ginseng polysaccharide extract, which is useful for liver protection or for the prevention and treatment of liver diseases, and a method for preparing the same. Further, the present invention relates to a composition for the prevention and treatment of liver diseases, comprising the Panax ginseng polysaccharide extract as an active ingredient, and a food composition comprising the same.

Abstract: The present invention provides a method for detecting senescence in tumor cells and a kit for detecting senescence in tumor cells. eEF1A1 and CD markers are provided, wherein changes in the levels of the markers are correlated with premature senescence of tumor cells.

Abstract: A target apparatus for producing a radioisotope having improved cooling performance including a cavity member including a cavity accommodating H218O concentrate and producing 18F through a nuclear reaction between the H218O concentrate and protons irradiated onto the H218O concentrate, wherein the cavity member includes a front aperture and a rear aperture disposed in opposite directions on a path in which the protons are irradiated and connected to the cavity so that the cavity has openings. wherein a thermo-chemically stable layer plated with titanium or niobium is formed in an inner circumference of the cavity.

Abstract: Provided are an isolated protein derived from an N-terminal of HveA/HVEM and having activity of increasing the cell infectivity of herpes simplex virus (HSV) and use thereof.

Abstract: Provided are a pileus-gills type helium condenser and an apparatus, including the same, for condensing helium. The pileus-gills type helium condenser includes: a body having a hemispheric shape and formed of a highly thermally conductive metal; a plurality of cooling fins collectively having a pileus gills-like shape and arranged along the circumference of the body to be spaced apart from one another; and a through-hole formed in the center of the body to be adjacent to the cooling fins.

Abstract: A radiotherapeutic system including non-invasive and real-time tumor tracking includes: a signal detector for detecting radioactive rays emitted from a tumor to which the radioactive medical supply is adsorbed and generating an electrical signal; a signal processor for converting the electrical signal generated into a three-dimensional (3D) coordinate signal; a controller for generating a control signal in conjunction with the 3D coordinate signal output by the signal processor; and a radioactive-ray irradiation device for emitting radioactive rays to the tumor, wherein the amount of the radioactive rays is controlled by the controller.

Abstract: Disclosed herein are a composition for prevention or treatment of bone marrow damage comprising Substance-P as an active ingredient; a use of Substance-P for the preparation of a medicament for prevention or treatment of bone marrow damage; a method for prevention or treatment of bone marrow damage comprising administering a therapeutically effective amount of Substance-P to a mammal; an anticancer supplement comprising Substance-P as an active ingredient; a use of Substance-P for the preparation of an anticancer supplement; and a method for prevention or treatment of cancer comprising administering a therapeutically effective amount of Substance-P as an anticancer supplement to a mammal. Substance-P stimulates proliferation of mesenchymal stem cells (MSCs) within the bone marrow to thereby facilitate protection and regeneration of bone marrow cells and hematopoietic stem cells.

Abstract: Provided is a collimator device for radiotherapy including: a body including a first through unit and disposed on a path of high energy radiation which in use is irradiated toward a patient's treatment part; a frame including a through hole corresponding to the first through unit and slidably installed in the body; a plurality of multi-leaf collimators (MLCs) slidably installed in the through hole and including radiation shields; a servo motor coupled to the body and the frame in a power manner so as to slidingly move the frame with respect to the body; and a motor controller externally receiving position displacement data regarding a motion of the patient's treatment part due to a patient's breathing and generating a signal for controlling the driving of the servo motor so that the MLCs follow the patient's treatment part and continuously apply radiation to the patient's treatment part based on the position displacement data.

Abstract: Provided is a composition for cancer treatment including phytosphingosine or a derivative thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention provides a composition for treating damage of central or peripheral nerve system comprising neural precursor cell derived from subcutaneous tissue; neuron obtained by differentiating the neural precursor cell; or oligodendrocyte or Schwann cell obtained by differentiating the neural precursor cell; a use of neural precursor cell derived from subcutaneous tissue, neuron obtained by differentiating the neural precursor cell, or oligodendrocyte or Schwann cell obtained by differentiating the neural precursor cell, for the manufacture of an agent for treating damage of central or peripheral nerve system; a method for treating damage of central or peripheral nerve system which comprises administrating to a mammal a therapeutically effective amount of neural precursor cell derived from subcutaneous tissue, neurons obtained by differentiating the neural precursor cell, or oligodendrocyte or Schwann cell obtained by differentiating the neural precursor cell.